Overview

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

Status:
Completed
Trial end date:
2018-10-11
Target enrollment:
Participant gender:
Summary
This is a Phase 1, Multicenter, Open-Label, Parallel Group Adaptive Pharmacokinetic Single Dose Study of ISIS 681257 Subcutaneous Injections in Male And Female Subjects with Normal and Impaired Renal Function
Phase:
Phase 1
Details
Lead Sponsor:
Akcea Therapeutics
Collaborator:
Ionis Pharmaceuticals, Inc.